

- Molecular imaging of ovarian cancer:** Sharma and colleagues survey recent advances and emerging innovations in MR, PET, SPECT, ultrasound, and optical imaging of ovarian cancer. *Page 827*
- Brachytherapy with ^{177}Lu -AuNPs:** Ehlerding and Cai offer perspective on brachytherapy in locally advanced breast cancer and preview a related article in this issue of *JNM* on intratumorally injected gold nanoparticles labeled with radiotherapeutic ^{177}Lu *Page 834*
- ^{131}I and cataracts:** Lin and colleagues evaluate associations between ^{131}I therapy and cataract surgery over a 10-year period after thyroid cancer treatment. *Page 836*
- PET textural features in NSCLC:** Ohri and colleagues use cooperative trial data to determine whether heterogeneity metrics from ^{18}F -FDG PET textural features can provide prognostic information in patients treated with chemoradiation for locally advanced non-small cell lung cancer. *Page 842*
- Background-adapted response assessment:** Burger and colleagues investigate correlations between background-subtracted lesion activity/background-subtracted volume on ^{18}F -FDG PET and histopathologic response after chemotherapy in non-small cell lung carcinoma. *Page 849*
- PET/CT lung cancer therapy response:** Sheikhabaie and colleagues assess the value of an ^{18}F -FDG PET/CT-based 5-point Hopkins interpretation system in predicting therapy response and survival in lung cancer. *Page 855*
- Kinetic analysis of ^{11}C -erlotinib:** Yaqub and colleagues identify an optimal pharmacokinetic model for quantification of ^{11}C -erlotinib uptake in patients with non-small cell lung cancer and evaluate simplified methods for routine analysis. *Page 861*
- ^{68}Ga -labeled ABY-025 dosimetry:** Sandström and colleagues measure biodistribution and estimate radiation dosimetry for this radiolabeled Affibody molecule in 2 different peptide mass doses using dynamic and serial whole-body PET/CT in patients with metastatic breast cancer. *Page 867*
- Assessing ^{68}Ga -DOTATATE:** Deppen and colleagues report on a systematic review and analysis of the safety and efficacy of ^{68}Ga -DOTATATE PET/CT compared with octreotide and conventional imaging to determine whether available evidence supports FDA approval. *Page 872*
- PET/CT in endometrial cancer:** Bollineni and colleagues analyze the reported diagnostic performance of ^{18}F -FDG PET/CT for preoperative assessment of lymph node metastases in endometrial cancer and in recurrence after primary surgical treatment. *Page 879*
- Na^{18}F PET/CT in advanced prostate cancer:** Apolo and colleagues detail the results of a pilot study on Na^{18}F PET/CT detection and monitoring of bone metastases in advanced prostate cancer and identify correlations with clinical outcomes and survival. *Page 886*
- SPECT quantification and dose reduction:** Palyo and colleagues demonstrate the dose reduction capabilities of a hybrid cadmium-zinc-telluride SPECT/64-slice CT system and determine the maximum reduction possible without compromising image quality or myocardial perfusion quantification precision. *Page 893*
- Interpreting florbetaben PET:** Seibyl and colleagues test the robustness of visual assessment in ^{18}F -florbetaben scans, comparing efficacy readouts across different interpreters and training methods and against a histopathology standard in end-of-life patients with and without dementia. *Page 900*
- ^{18}F -FDG and ^{11}C -acetate PET/CT dosimetry:** Liu and colleagues characterize the radiation dosimetry of this combined whole-body dual-tracer PET/CT protocol used in staging patients with hepatocellular carcinoma. *Page 907*
- MR AC and amyloid PET:** Su and colleagues investigate the impact of a standard MR attenuation correction technique on the clinical and research utility of a hybrid PET/MR scanner in assessment of amyloid status. *Page 913*
- Brain PET/MR AC:** Koesters and colleagues describe a novel attenuation correction method that supplements standard Dixon-based tissue segmentation with a superimposed model-based bone compartment in simultaneous PET and MR brain imaging. *Page 918*
- Albumin microspheres in radioembolization:** Grosser and colleagues explore the intrahepatic and intrapulmonary stability of $^{99\text{m}}\text{Tc}$ -macroaggregated serum albumin and $^{99\text{m}}\text{Tc}$ -human serum albumin for perfusion scintigraphy before hepatic radioembolization with ^{90}Y -microspheres. *Page 925*
- Lymphoma response assessment criteria:** Moghbel and colleagues provide an educational overview of existing response assessment criteria for lymphoma, highlighting their respective methodologies and reviewing evidence for validity. *Page 928*
- ^{177}Lu gold nanoseed brachytherapy:** Yook and colleagues study intratumorally injected ^{177}Lu -labeled gold nanoparticles modified to target epidermal growth factor receptors as a novel neoadjuvant brachytherapy approach in preclinical models of locally advanced breast cancer. *Page 936*
- Targeting CAIX-positive kidney cancer:** Krall and colleagues investigate the biodistribution of a novel carbonic anhydrase ligand with high affinity for the tumor-associated isoform IX and assess evidence supporting further development of acetazolamide conjugates as drug carriers and radioimaging agents. *Page 943*
- Imaging MC-I activity in PD:** Tsukada and colleagues describe the use of ^{18}F -BCPP-EF PET to assess mitochondrial complex I activity and damage in the brains of nonhuman primate models of Parkinson disease. *Page 950*
- Neuroinflammation and amyloidosis in AD mice:** Brendel and colleagues detail the results of a triple-tracer small-animal PET investigation to study microglial activation and glucose metabolism in association with amyloid plaque load in a transgenic Alzheimer disease mouse model. *Page 954*
- Hepatobiliary secretion kinetics:** Sørensen and colleagues develop a method for ^{11}C -CSar PET quantification of hepatobiliary uptake and secretion of conjugated bile acids in pigs. *Page 961*
- ^{18}F -labeled anti-HER2 Nanobody:** Vaidyanathan and colleagues use 2 methods to evaluate the tumor-targeting potential of an anti-human growth factor receptor type 2 Nanobody for applications in immuno-PET assessment of HER2 status. *Page 967*
- ^{89}Zr -DS-8895a imaging of EphA2:** Burvenich and colleagues report on preclinical SPECT/MR and PET/MR imaging of subtype A2 of the erythropoietin-producing hepatocellular tyrosine kinase, a cell surface receptor expressed in a range of epithelial cancers. *Page 974*
- ACKR3/CXCR7 tumor imaging:** Behnam Azad and colleagues describe evaluation of a radiolabeled atypical chemokine receptor-targeted monoclonal antibody for noninvasive nuclear imaging of ACKR3 expression in human breast, lung, and esophageal squamous cell carcinoma xenografts. *Page 981*